Advances in induction of ovulation.
The emphasis of this review is placed on the treatment of clomiphene-resistant women with polycystic ovary syndrome (PCOS) or with hypogonadotropic hypogonadism. There has been an increasing awareness of the need to avoid the consequences of multiple folliculogenesis, and this is reflected in the more widespread use of low-dose regimens for induction of ovulation, particularly in PCOS. The past 12 months have seen the first reports of the clinical applications of recombinant human follicle-stimulating hormone (FSH), and there is an intriguing suggestion that long-acting opiate agonists may have a part to play in the management of anovulation of hypothalamic origin.
Franks
S
S
Department of Obstetrics and Gynaecology, Imperial College of Science Technology and Medicine, St. Mary's Hospital Medical School, London, UK.
Gilling-Smith
C
C
D002064:Buserelin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002996:Clomiphene / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006062:Gonadotropins / Q000627:therapeutic use; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D009271:Naltrexone / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000517:prevention & control; D010062:Ovulation Induction / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome
D006062:Gonadotropins; D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D009271:Naltrexone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D002064:Buserelin